BioLens · Lunartree
Experience BioLens
See BioLens in action
A guided walkthrough of how teams actually use BioLens — pick a use case below to see it running.
Shown as: WuXi Biologics business development teamSearch & evaluate companies
As WuXi Biologics, find and evaluate the biotech and pharma programs that need biologics discovery, development, or manufacturing support.
Typing a search for ADC-focused biotech targets.
What are you looking for?
Top matches
0 accounts foundBiopharma R&D
As WuXi Biologics, evaluate biologics pipeline programs at biotech and pharma companies and prioritize which ones to court.
Scoring biologics programs against WuXi Biologics' partnership criteria.
timing 16%
fit 14%
partner 12%
CDMO BD & outreach
As WuXi Biologics, turn a high-priority account signal into a drafted outreach email to the right decision maker.
Reviewing AbCellera Biologics Inc. for outreach priority.
AbCellera Biologics Inc.
+24 SignalsInitiate Strategic Outreach to AbCellera Post-Funding and Clinical Milestones
AbCellera's $200M offering and strong Phase 2 results signal an urgent window to position WuXi Biologics as a manufacturing partner for late-stage and commercial-scale needs.
Operations & Manufacturing
Mark Skoog at AbCellera Biologics Inc.
Competitive intelligence
As WuXi Biologics, monitor account signals and ask an AI copilot how to act on them.
Reviewing Biohaven's account signals and recommended AI copilot questions.
Biohaven, Ltd.
Publicly traded, mid-size biotech with multiple in-scope biologic assets (ADCs, recombinant protein degraders) in pivotal Phase II/III trials, and $400M in fresh non-dilutive funding. Diversified pipeline and strong financial posture make Biohaven a high-priority BD target, despite regulatory risk from the BHV-7000 clinical hold.
CRM sync
As WuXi Biologics, push BioLens account intelligence straight into your Salesforce CRM.
Review an account in BioLens, then push it to Salesforce.
AbCellera Biologics Inc.
High-priority BD target: $200M public offering, strong Phase 2 results, and an active manufacturing vendor evaluation window.
Biohaven, Ltd.
High-priority BD target: $400M non-dilutive funding from SK Biopharmaceuticals and a pivotal-stage biologics pipeline.
Apogee Therapeutics
High-priority BD target: Phase 2 mAb pipeline with strong modality fit and no disclosed manufacturing partner.